top of page
  • Writer's pictureKirk Hartley

The Molecular Revolution Continues – Foundation Medicine’s Mutation Testing for Solid Tu

The molecular biology revolution continues, and is relevant to toxic tort claiming. Consider, for example, whether tumors such as mesothelioma are driven by external “toxins,” genetic mutations, or both.

Until recently, testing for genetic mutations in tumors was difficult and expensive.  That’s no longer true. Consider the tumor mutation testing products of  one prominent new player in the molecular revolution:  Foundation Medicine.

Foundation Medicine now sells the following solid tumor mutation test in the US, and is taking the product global. The following is taken from a recent press release from Foundation Medicine:

“About FoundationOne®

        FoundationOne, the company’s first clinical product, is a fully informative genomic profile for solid tumors used by oncologists to identify the molecular alterations in a patient’s tumor and match those alterations with relevant targeted therapies and clinical trials. Using next-generation sequencing in routine cancer specimens, FoundationOne interrogates all genes somatically altered in human cancers that are validated targets for therapy or unambiguous drivers of oncogenesis based on current knowledge. It reveals all classes of genomic alterations including base substitutions, insertions, deletions, copy number alterations and select rearrangements. FoundationOne fits easily into the clinical workflow of the ordering physician, and test results are provided in an easy-to-interpret report supported by a comprehensive review of published literature. FoundationOne is a laboratory-developed test performed at Foundation Medicine’sCLIA-certified lab. Please visit for more information.

About Foundation Medicine

Foundation Medicine (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, provide a fully informative genomic profile to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc.”

2 views0 comments

Recent Posts

See All


bottom of page